Home › Employers › Alabama Cancer Care, LLC
Alabama Cancer Care, LLC: H-1B salaries and sponsorship
Alabama Cancer Care, LLC filed 4 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $400,000.
Does Alabama Cancer Care, LLC sponsor H-1B visas?
Alabama Cancer Care, LLC filed 4 labor condition applications in fiscal years 2023–2026, the latest submitted on Apr 22, 2025. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Hematologist/Medical Oncologist | 4 | $400,000 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2024 | 1 | $400,000 |
| FY2025 | 2 | $650,000 |
| FY2026 | 1 | $400,000 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Hematologist/Medical Oncologist | $650,000 Level II | Tuscaloosa, AL | Apr 22, 2025 | Jul 31, 2025 | Certified |
| Hematologist/Medical Oncologist | $650,000 Level II | Tuscaloosa, AL | Apr 22, 2025 | Jul 31, 2025 | Withdrawn |
| Hematologist/Medical Oncologist | $400,000 Level II | Montgomery, AL | Mar 26, 2024 | Aug 1, 2024 | Certified |
| Hematologist/Medical Oncologist | $400,000 Level II | Montgomery, AL | Jul 7, 2021 | Aug 1, 2021 | Certified, then withdrawn |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).